CCM
DNTH icon

Corsair Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Corsair Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,250
Closed -$75.8K – 103
2023
Q2 		$75.8K Buy
6,250
+4,197
+204% +$47.7K 0.03% 98
2023
Q1 		$26.1K Buy
+2,053
New +$22.7K 0.01% 90

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Corsair Capital Management's DNTH Position: Q3 2023 in Review

Corsair Capital Management sold out of Dianthus Therapeutics (DNTH) in Q3 2023, closing a stake of 6,250 shares — an estimated $75.8K sold.

Corsair Capital Management first reported a position in DNTH in Q1 2023 and held it in 2 quarters. The position peaked at $75.8K in Q2 2023. 30 funds tracked by Wall St. Rank hold DNTH as of Q3 2023.

  • Corsair Capital Management reported no remaining Dianthus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Corsair Capital Management sold 6,250 Dianthus Therapeutics shares in Q3 2023, an estimated $75.8K.
  • Corsair Capital Management first reported a position in Dianthus Therapeutics in Q1 2023 and held it in 2 quarters.
  • Corsair Capital Management's Dianthus Therapeutics position peaked at $75.8K in Q2 2023.
  • 30 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2023.

Based on Corsair Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.